Monozeclar (Clarithromycin)

Clarithromycin, the active ingredient in Monozeclar, is a macrolide antibiotic presented as an oral tablet for systemic use. It treats bacterial infections such as community‑acquired pneumonia, acute sinusitis, bronchitis, skin infections, and is used in combination regimens for Helicobacter pylori eradication.

GNH USA supplies Monozeclar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable supply chains, comprehensive documentation, and responsive technical support.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections in the respiratory, ENT, skin, and gastrointestinal systems. - Community‑acquired pneumonia: eliminates causative bacteria and improves clinical recovery. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Acute bacterial bronchitis: relieves cough and eradicates the pathogen. - Skin and soft tissue infections: treats cellulitis and other bacterial skin conditions. - Helicobacter pylori eradication (in combination therapy): contributes to successful bacterial clearance as part of triple‑therapy regimens.

Adverse reactions may occur with clarithromycin therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Vomiting: occasional emesis. - Headache: mild to moderate.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - QT prolongation: may lead to cardiac arrhythmias. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Clostridioides difficile‑associated diarrhea: severe colitis. - Cardiac arrhythmias: including torsades de pointes. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Use clarithromycin with caution and follow medical guidance. - Renal or hepatic impairment: adjust therapy under professional supervision. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Drug resistance: limit use to confirmed bacterial infections to avoid resistance development. - Cardiac risk: avoid in patients with known QT‑interval prolongation. - Drug interactions: review all concomitant medications for potential interactions. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Clarithromycin can interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Erythromycin: additive risk of QT prolongation. - Cisapride: may cause serious cardiac arrhythmias. - Theophylline: clarithromycin inhibits metabolism, raising serum levels.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Statins (lovastatin, simvastatin): heightened risk of myopathy; check creatine kinase levels.